P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction

Thrombosis Research

Volumn 130, Issue 3, 2012, Pages

  Diego, Alejandro ^a   De Prado, Armando Pérez ^a   Cuellas, Carlos ^a   De Miguel, Antonio ^a   Samaniego, Beatriz ^a   Alonso Rodríguez, David ^a   Bangueses, Roi ^a   Vega, Berta ^a   Martín, Julia ^a   Fernandez Vazquez, Felipe ^a  

^a UNIVERSITY OF LEÓN   (Spain)

Author keywords

Acute myocardial infarction; Elective angiography; Platelet reactivity; Response to clopidogrel; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; PANTOPRAZOLE; PURINERGIC P2Y12 RECEPTOR; STREPTOKINASE; TENECTEPLASE;

ADULT; ANGIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; IMMUNOREACTIVITY; LOADING DRUG DOSE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT RESPONSE;

ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2Y12; THROMBOLYTIC THERAPY; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84865233125     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.05.031     Document Type: Article

References (43)

1. E.C. Keeley, J.A. Boura, and C.L. Grines Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials Lancet 361 2003 13 20
2. W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, and T. Folliguet Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
3. P.G. Steg, E. Bonnefoy, S. Chabaud, F. Lapostolle, P.Y. Dubien, and P. Cristofini Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: Data from the captim randomized clinical trial Circulation 108 2003 2851 2856
4. M.L. Simoons, A.E. Arnold, A. Betriu, D.P. de Bono, J. Col, and F.C. Dougherty Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty Lancet 1 1988 197 203
5. M.P. Hudson, C.B. Granger, E.J. Topol, K.S. Pieper, P.W. Armstrong, and G.I. Barbash Early reinfarction after fibrinolysis: Experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (gusto i) and global use of strategies to open occluded coronary arteries (gusto iii) trials Circulation 104 2001 1229 1235
6. C.M. Gibson, J. Karha, S.A. Murphy, D. James, D.A. Morrow, and C.P. Cannon Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials J Am Coll Cardiol 42 2003 7 16
7. F.W. Verheugt, A. Meijer, W.K. Lagrand, and M.J. Van Eenige Reocclusion: The flip side of coronary thrombolysis J Am Coll Cardiol 27 1996 766 773
8. F. Fernandez-Aviles, J.J. Alonso, A. Castro-Beiras, N. Vazquez, J. Blanco, and J. Alonso-Briales Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with st-segment elevation (gracia-1): A randomised controlled trial Lancet 364 2004 1045 1053
9. P.W. Armstrong A comparison of pharmacologic therapy with/without timely coronary intervention vs. Primary percutaneous intervention early after st-elevation myocardial infarction: The west (which early st-elevation myocardial infarction therapy) study Eur Heart J 27 2006 1530 1538
10. F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, and V. Falk Esc guidelines on management of acute myocardial infarction in patients presenting with persistent st-segment elevation Rev Esp Cardiol 62 293 2009 e291 e
11. B. Scheller, B. Hennen, B. Hammer, J. Walle, C. Hofer, and V. Hilpert Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction J Am Coll Cardiol 42 2003 634 641
12. M.R. Le May, G.A. Wells, M. Labinaz, R.F. Davies, M. Turek, and D. Leddy Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (capital ami study) J Am Coll Cardiol 46 2005 417 424
13. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with st-segment elevation acute myocardial infarction (assent-4 pci): Randomised trial Lancet 367 2006 569 578
14. P.W. Armstrong, and D. Collen Fibrinolysis for acute myocardial infarction: Current status and new horizons for pharmacological reperfusion, part 2 Circulation 103 2001 2987 2992
15. D.J. Fitzgerald, F. Catella, L. Roy, and G.A. FitzGerald Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction Circulation 77 1988 142 150
16. B.S. Coller Platelets and thrombolytic therapy N Engl J Med 322 1990 33 42
17. G. Rasmanis, O. Vesterqvist, K. Green, O. Edhag, and P. Henriksson Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction Br Heart J 68 1992 374 376
18. C. Bihour, C. Durrieu-Jais, P. Besse, P. Nurden, and A.T. Nurden Flow cytometry reveals activated gp iib-iiia complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction Blood Coagul Fibrinolysis 6 1995 395 410
19. N.J. Frandsen, K. Winther, F. Pedersen, I. Christiansen, and P. McNair Time course of platelet alpha granule release in acute myocardial infarction treated with streptokinase Heart 75 1996 141 144
20. M. Moser, T. Nordt, K. Peter, J. Ruef, B. Kohler, and M. Schmittner Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase Circulation 100 1999 1858 1864
21. P.A. Gurbel, V.L. Serebruany, A.R. Shustov, R.D. Bahr, C. Carpo, and E.M. Ohman Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. Gusto-iii investigators. Global use of strategies to open occluded coronary arteries J Am Coll Cardiol 31 1998 1466 1473
22. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. Lopez-Sendon, G. Montalescot, and P. Theroux Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with st-elevation myocardial infarction treated with fibrinolytics: The pci-clarity study JAMA 294 2005 1224 1232
23. J.W. van Werkum, C.A. van der Stelt, T.H. Seesing, C.M. Hackeng, and J.M. ten Berg A head-to-head comparison between the verifynow p2y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention J Thromb Haemost 4 2006 2516 2518
24. N. von Beckerath, G. Pogatsa-Murray, A. Wieczorek, D. Sibbing, A. Schomig, and A. Kastrati Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness Thromb Haemost 95 2006 910 911
25. E.G. Bovill, M.L. Terrin, D.C. Stump, A.D. Berke, M. Frederick, and D. Collen Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the thrombolysis in myocardial infarction (timi), phase ii trial Ann Intern Med 115 1991 256 265
26. U. Zeymer, M. Mateblowski, and K.L. Neuhaus Thrombin generation in patients with acute myocardial infarction treated with front-loaded rt-pa and recombinant hirudin (hbw 023) J Thromb Thrombolysis 5 1998 203 207
27. W.J. Cantor, J. Burnstein, R. Choi, M. Heffernan, V. Dzavik, and C. Lazzam Transfer for urgent percutaneous coronary intervention early after thrombolysis for st-elevation myocardial infarction: The transfer-ami pilot feasibility study Can J Cardiol 22 2006 1121 1126
28. J.T. Brandt, S.L. Close, S.J. Iturria, C.D. Payne, N.A. Farid, and C.S. Ernest II Common polymorphisms of cyp2c19 and cyp2c9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436
29. E.R. Bates, W.C. Lau, and D.J. Angiolillo Clopidogrel-drug interactions J Am Coll Cardiol 57 2011 1251 1263
30. A.J. Scheen, and D. Legrand Aspirin and clopidogrel resistance in patients with diabetes mellitus Eur Heart J 27 2006 2900 [author reply 2900-2901]
31. T. Geisler, M. Kapp, K. Gohring-Frischholz, K. Daub, C. Dosch, and B. Bigalke Residual platelet activity is increased in clopidogrel- and asa-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease Heart 94 2008 743 747
32. T. Cuisset, M. Hamilos, J. Sarma, G. Sarno, E. Wyffels, and M. Vanderheyden Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris Am J Cardiol 101 2008 1700 1703
33. A. de Miguel Castro, C. Cuellas Ramon, A. Diego Nieto, B. Samaniego Lampon, D. Alonso Rodriguez, and F. Fernandez Vazquez Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-st-segment elevation acute coronary syndrome Rev Esp Cardiol 62 2009 126 135
34. M.J. Price, D.J. Angiolillo, P.S. Teirstein, E. Lillie, S.V. Manoukian, and P.B. Berger Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the gauging responsiveness with a verifynow p2y12 assay: Impact on thrombosis and safety (gravitas) trial Circulation 124 2011 1132 1137
35. A.T. Yan, R.T. Yan, W.J. Cantor, B. Borgundvaag, E.A. Cohen, and D.H. Fitchett Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: Insights from the trial of routine angioplasty and stenting after fibrinolysis to enhance reperfusion in acute myocardial infarction (transfer-ami) Eur Heart J 32 2011 1994 2002
36. A. Perez de Prado, F. Fernandez-Vazquez, J.C. Cuellas, N. Alonso-Orcajo, R. Carbonell, and C. Pascual Association between level of platelet inhibition after early use of abciximab and myocardial reperfusion in st-elevation acute myocardial infarction treated by primary percutaneous coronary intervention Am J Cardiol 97 2006 798 803
37. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, and C. Banuelos High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability Eur Heart J 25 2004 1903 1910
38. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
39. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
40. D.J. Angiolillo, D. Capodanno, and S. Goto Platelet thrombin receptor antagonism and atherothrombosis Eur Heart J 31 2010 17 28
41. P. Tricoci, Z. Huang, C. Held, D.J. Moliterno, P.W. Armstrong, and F. Van de Werf Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N Engl J Med 366 2012 20 33
42. D.A. Morrow, B.M. Scirica, K.A. Fox, G. Berman, J. Strony, and E. Veltri Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (tra 2 degrees p)-timi 50 trial Am Heart J 158 2009 335 341 e333
43. J.A. Jakubowski, C.D. Payne, Y.G. Li, J.T. Brandt, D.S. Small, and N.A. Farid The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition leveles following prasugrel and clopidogrel administration Thromb Haemost 99 2008 409 415